L'intérêt à découvert pour Centene donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Centene. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Centene (NYSE:CNC) Stock, Rapport sur les intérêts à découvert

Centene

Centene is a managed care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of September, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare Advantage (about 5%). The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program and has a military contract.

Centene Corp

Canna Corp

CHINA NUCLEAR ENERGY TECH by CHINA NUCLEAR ENERGY TECHNOLOGY CORP LTD.

CANCER CAPITAL CORP by Cancer Capital Corp.

Cancer Capital Corp

CONNECTED MEDIA TECHS INC by Connected Media Technologies, Inc.

Connected Media Technologies Inc

CHUN CAN CAPITAL GROUP by Chun Can Capital Group

Chun Can Capital Group

Core Nickel Corp

CONDUIT CAPITAL LTD ORD by Conduit Capital Ltd.

Range Cancer Therapeutics ETF

CHINA CASTSON 81 FINCE by CHINA CASTSON 81 FINANCE CO.

CHINA TELETECH HLDGS INC by China Teletech Holding, Inc.

China Teletech Holding Inc

WIIM

Shares of health insurance stocks are trading higher in possible reaction to President-elect Donald Trump indicating he plans to nominate Dr. Mehmet Oz as administrator for the Centers for Medicare and Medicaid Services. Oz has reportedly supported Medicare Advantage plans.

Centene's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) short percent of float has risen 87.36% since its last report. The company recently reported that it has 14.44 million shares sold short, which is 3.26% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.7 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Centene Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732023024_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Centene has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Centene's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Centene's peer group average for short interest as a percentage of float is 4.59%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into Centene's Recent Short Interest

News

Guidance

Centene Plans To Reaffirm 2024 Adjusted EPS Guidance Of Greater Than $6.80 (Est $6.69); Also Plans To Reiterate That It Expects To Grow Adjusted EPS In 2025 And Beyond - Filing

On Wednesday, Donald Trump, the Republican candidate and former president, was elected to the highest office again, marking a return to an administration. His second term is likely to impact U.S. healthcare.
Trump has been unclear about his healthcare policy goals during his campaign. Healthcare <a target="_blank" href="https://www.kff.org/health-care-in-2024-elections-apvotecast-polling/?entry=kff-analysis-of-ap-votecast-abortion-ballot-initiatives" rel="noreferrer noopener">ranked</a> lower than issues like the economy and immigration in voter concerns.
A <a target="_blank" href="https://apnews.com/article/ap-votecast-elections-harris-trump-voters-d5cf4e3611f50ec4349d93ddc7f037cd" rel="noreferrer noopener">poll</a> from the Associated Press found that only 8% of voters viewed healthcare as their top issue, compared to 39% who chose the economy and 20% who picked immigration. Abortion was the leading issue for 11% of voters.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction" rel="noreferrer noopener">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a>
Despite his focus on &#8220;Make America Healthy Again,&#8221; millions of Americans may lose health insurance subsidies next year, depending on the political climate after the election and the Republicans&#8217; control of the Senate.
The subsidies, expanded under the 2021 American Rescue Plan, help many, particularly the middle class, afford health insurance through the Affordable Care Act (ACA).
These subsidies are set to expire at the end of 2025, and it remains uncertain whether they will be extended under the new administration.
Trump and other Republicans have opposed continuing the subsidies.
The NBC News <a target="_blank" href="https://www.nbcnews.com/health/health-news/millions-risk-losing-health-insurance-trumps-victory-rcna179146" rel="noreferrer noopener">report</a>, citing some analysts, suggests that the chances of extension could be less than 5% if Republicans win control of the House and the Senate.
Even if Democrats control the House, extending these subsidies seems unlikely. Without an extension, nearly 4 million Americans could lose coverage by 2026 due to unaffordable premiums.
The 2021 changes led to a surge in ACA enrollment, with 15.5 million people benefiting from subsidies across 32 states. The report adds that if the subsidies aren&#8217;t renewed, up to 15.4 million Americans could lose health coverage by 2030.
Another significant issue is Trump&#8217;s stance on Medicare. As president, he supported Medicare Advantage, a private insurer-run program that could eventually replace traditional, government-run Medicare.
The NPR report <a target="_blank" href="https://www.npr.org/sections/shots-health-news/2024/11/07/nx-s1-5183092/trump-election-2024-medicare-advantage" rel="noreferrer noopener">highlights</a> that critics argue that expanding private insurers could increase costs for taxpayers and limit care, with some beneficiaries finding it difficult to switch back to traditional Medicare.
Robert Berenson, a former government official, warned that traditional Medicare could &#8220;wither on the vine.&#8221;
Medicare Advantage grew with the 2003 legislation introducing a drug benefit and expanded private insurers&#8217; role in the program. Although private plans were expected to lower costs, they have been more expensive.
The report also says that in 2023, Medicare Advantage plans cost taxpayers about 6% — or $27 billion — more than traditional Medicare, though some research suggests they offer better care.
The future of healthcare policy in the U.S. will depend on the political dynamics in Congress and Trump&#8217;s second term.
With Republicans pushing for major changes to the ACA and Medicare, experts warn of significant shifts in how Americans access and pay for healthcare in the coming years.
Read Next
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41855578/bristol-myers-squibb-leads-biopharma-recovery-with-almost-25-growth-in-market-cap-but-novo-nordisk-and-lilly-suffer-market-setbacks" target="_blank" rel="noreferrer noopener">Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks</a></li>
</ul>
Photo via Shutterstock

Government

Regulations

Health Care

Politics

Markets

General

ALHC

CLOV

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Laboratory Corporation Of America Holdings

Donald Trump's Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare

Centene's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) short percent of float has risen 3.57% since its last report. The company recently reported that it has 8.09 million shares sold short, which is 1.74% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.97 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Centene Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730812513_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Centene has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Centene's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Centene's peer group average for short interest as a percentage of float is 4.34%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(CNC) - Analyzing Centene's Short Interest

Wells Fargo analyst Stephen Baxter maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Overweight and lowers the price target from $91 to $90.

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Centene, Lowers Price Target to $90

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4293554-1&amp;h=3420507561&amp;u=https%3A%2F%2Fwww.centene.com%2F&amp;a=Centene+Corporation">Centene Corporation</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), a leading healthcare enterprise committed to helping people live healthier lives, announced today that its subsidiary, <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4293554-1&amp;h=1525079035&amp;u=https%3A%2F%2Fwww.buckeyehealthplan.com%2F&amp;a=Buckeye+Health+Plan">Buckeye Health Plan</a>&nbsp;(Buckeye), has been selected by the Ohio Department of Medicaid (ODM) to continue providing Medicare and Medicaid services for dually eligible individuals through a Fully Integrated Dual Eligible Special Needs Plan (FIDE SNP). FIDE SNPs fully integrate care for dually eligible beneficiaries under a single managed care organization, allowing enrollees to receive all of their medical, behavioral and long-term services and supports through one plan.

Biotech

Centene's Buckeye Health Plan Awarded Contract To Serve Dual Eligible Medicare And Medicaid Members In Ohio

Bernstein analyst Lance Wilkes maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Outperform and lowers the price target from $96 to $88.

Bernstein Maintains Outperform on Centene, Lowers Price Target to $88

Barclays analyst Andrew Mok maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Overweight and lowers the price target from $97 to $91.

Barclays Maintains Overweight on Centene, Lowers Price Target to $91

Investors with a lot of money to spend have taken a bearish stance on Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CNC, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 14 uncommon options trades for Centene.
This isn't normal.
The overall sentiment of these big-money traders is split between 35% bullish and 64%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $164,810, and 9 are calls, for a total amount of $443,199.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $62.0 to $72.5 for Centene during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Centene's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Centene's substantial trades, within a strike price spectrum from $62.0 to $72.5 over the preceding 30 days.
<h3>Centene Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729886449_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CNC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.15</td>
<td>$2.05</td>
<td>$2.15</td>
<td>$67.50</td>
<td>$75.7K</td>
<td>526</td>
<td>815</td>
</tr>
<tr>
<td>CNC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$6.6</td>
<td>$6.4</td>
<td>$6.55</td>
<td>$62.50</td>
<td>$64.1K</td>
<td>350</td>
<td>143</td>
</tr>
<tr>
<td>CNC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$6.1</td>
<td>$5.7</td>
<td>$5.75</td>
<td>$65.00</td>
<td>$59.4K</td>
<td>105.3K</td>
<td>513</td>
</tr>
<tr>
<td>CNC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$1.15</td>
<td>$1.0</td>
<td>$1.15</td>
<td>$72.50</td>
<td>$57.5K</td>
<td>1.2K</td>
<td>781</td>
</tr>
<tr>
<td>CNC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$1.0</td>
<td>$0.95</td>
<td>$1.0</td>
<td>$72.50</td>
<td>$46.1K</td>
<td>1.2K</td>
<td>1.6K</td>
</tr>
</tbody>
</table>

<h3>About Centene</h3>
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of June 2023, mostly in Medicaid (67% of membership), the individual exchanges (14%), and Medicare Advantage (6%) plans. The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program.
In light of the recent options history for Centene, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Centene</h3>
<ul>
<li>Trading volume stands at 9,607,957, with CNC's price up by 4.68%, positioned at $64.5.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 0 days.</li>
</ul>
<h3>Professional Analyst Ratings for Centene</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $78.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $90. 
&#x2A; Consistent in their evaluation, an analyst from Baird keeps a Neutral rating on Centene with a target price of $66. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Centene options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Centene Options Trading: A Deep Dive into Market Sentiment

Stocks are ending the week on a high note, with tech leading the charge as investors position ahead of next week&#8217;s pivotal earnings releases from <a href="https://www.benzinga.com/topic/magnificent-7">five of the &#8220;Magnificent Seven&#8221; stocks.</a>
Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>), Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) will all report quarterly earnings between Oct. 29 and Oct. 31.
Combined, nearly 45% of the S&amp;P 500 by market cap is set to report results next week, with other heavyweights including McDonald&#8217;s Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>), Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Mastercard Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>), Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) and Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>).
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) continued its upward trajectory on Friday, rising 2.7% following a massive 21% jump on Thursday — its biggest one-day gain since May 2013.
The S&amp;P 500 was up 0.5% at midday trading in New York, while the Nasdaq 100 surged by 1.5%, fueled by semiconductor stocks. 
The Dow Jones Industrial Average fell 0.3%, on track to end a six-week winning streak. The U.S. dollar strengthened further, with the DXY Index rising past the 104 mark, setting up for a fourth straight week of gains. Meanwhile, Treasury yields were steady. 
WTI crude rose 1.8%, driven by concerns over geopolitical tensions in the Middle East. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is up slightly at $67,695.
<h1 class="wp-block-heading">Friday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % change</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,500.56</td>
<td>1.3%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,839.28</td>
<td>0.5%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,219.60</td>
<td>0.3%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,271.11</td>
<td>-0.3%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:50 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent102225&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.5% to $582.19.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;eased 0.2% to $423.18.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rallied 1.3% to $498.83.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) inched 0.2% up to $220.09.</li>
<li>The Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up by 1.4%. The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 0.9%.</li>
</ul>
<h1 class="wp-block-heading">Thursday&#8217;s Stock Movers</h1>
<ul>
<li>Capital One Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) rallied 7% to levels last seen in October 2021 on better-than-expected quarterly results. </li>
<li>Digital Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>) rallied over 10% after reporting record new lease bookings. </li>
</ul>
Other stocks reacting to earnings included:
<ul>
<li>Ameriprise Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>), down 0.13%</li>
<li>DexCom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), down 1%</li>
<li>ResMed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) up 7.6%, </li>
<li>Skechers U.S.A. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) down 0.2%, </li>
<li>Western Digital Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) up 7.6%, </li>
<li>Deckers Outdoor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>), up 11%</li>
<li>Edward Lifesciences Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), down by 0.6%</li>
<li>HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), down 10%, </li>
<li>Aon plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>), up 6%, </li>
<li>Colgate-Palmolive Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>), down 3.4%, </li>
<li>Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), up 6.7%, </li>
<li>Saia Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>), up 9.2%. </li>
</ul>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41549147/goldman-sachs-analyst-remains-bullish-on-boeing-despite-weak-q3-long-term-deep-valu">Goldman Sachs Analyst Remains Bullish On Boeing Despite Weak Q3: &#8216;Long-Term Deep-Value Opportunity</a>&#8216;</li>
</ul>
Photo: Shutterstock

Earnings

Equities

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

Economics

Tech

ETFs

$BTC

AAPL

AMZN

DECK

SPDR Dow Jones Industrial Average ETF Trust

DXCM

GOOG

GOOGL

MSFT

RIVN

SAIA

TSLA

Select Sector SPDR-Consumer Discretionary

Tech Stocks Rally As Investors Await Magnificent 7 Earnings; Dollar Eyes Fourth Straight Positive Week: What's Driving Markets Friday?

Across the recent three months, 13 analysts have shared their insights on Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $88.77, a high estimate of $98.00, and a low estimate of $66.00. This current average represents a 0.09% decrease from the previous average price target of $88.85. 
<img src="https://www.benzinga.com/files/images/story/2024/1729861241_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Centene is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$66.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$91.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$97.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$98.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$78.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$87.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$89.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$95.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Centene. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Centene compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Centene's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Centene's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CNC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Centene analyst ratings.</a>
<h2>Delving into Centene's Background</h2>
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of June 2023, mostly in Medicaid (67% of membership), the individual exchanges (14%), and Medicare Advantage (6%) plans. The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program.
<h3>Unraveling the Financial Story of Centene</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Centene displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 5.92%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Centene's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 2.88%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Centene's ROE excels beyond industry benchmarks, reaching 4.22%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Centene's ROA stands out, surpassing industry averages. With an impressive ROA of 1.38%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Centene's debt-to-equity ratio surpasses industry norms, standing at 0.64. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Key Takeaways From Centene Analyst Ratings

Baird analyst Michael Ha maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Neutral and lowers the price target from $83 to $66.

Baird Maintains Neutral on Centene, Lowers Price Target to $66

<h3>Gainers</h3>
<ul>
<li>TFF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) stock moved upwards by 27.9% to $2.63 during Friday's pre-market session. The company's market cap stands at $9.1 million. </li>
<li>Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) stock rose 12.62% to $69.4. The market value of their outstanding shares is at $36.5 billion. As per the news, the Q3 earnings report came out today. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares rose 9.31% to $2.35. The market value of their outstanding shares is at $24.8 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares increased by 8.76% to $1.31. The company's market cap stands at $93.4 million. </li>
<li>Actinium Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#AMEX">ATNM</a>) shares increased by 8.33% to $1.82. The company's market cap stands at $56.7 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) shares rose 8.11% to $2.93. The market value of their outstanding shares is at $23.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) stock fell 23.9% to $24.85 during Friday's pre-market session. The company's market cap stands at $87.4 million. </li>
<li>Quince Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNCX#NASDAQ">QNCX</a>) stock declined by 15.97% to $1.0. The company's market cap stands at $43.2 million. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock declined by 14.89% to $0.31. The market value of their outstanding shares is at $4.0 million. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) shares decreased by 11.01% to $0.65. The company's market cap stands at $3.7 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) stock fell 10.11% to $4.27. The market value of their outstanding shares is at $5.6 million. </li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) shares decreased by 9.91% to $0.58. The market value of their outstanding shares is at $35.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ATNM

BIVI

BNOX

CTOR

DWTX

HEPA

MNPR

PASG

QNCX

TFFP

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>TFF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) stock moved upwards by 27.9% to $2.63 during Friday's pre-market session. The market value of their outstanding shares is at $9.1 million. </li>
<li>Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) shares increased by 12.62% to $69.4. The market value of their outstanding shares is at $36.5 billion. As per the press release, Q3 earnings came out today. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares rose 9.31% to $2.35. The company's market cap stands at $24.8 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) stock rose 8.76% to $1.31. The company's market cap stands at $93.4 million. </li>
<li>Actinium Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#AMEX">ATNM</a>) stock moved upwards by 8.33% to $1.82. The company's market cap stands at $56.7 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock increased by 8.11% to $2.93. The company's market cap stands at $23.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) shares declined by 23.9% to $24.85 during Friday's pre-market session. The market value of their outstanding shares is at $87.4 million. </li>
<li>Quince Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNCX#NASDAQ">QNCX</a>) stock fell 15.97% to $1.0. The company's market cap stands at $43.2 million. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock decreased by 14.89% to $0.31. The company's market cap stands at $4.0 million. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) shares declined by 11.01% to $0.65. The market value of their outstanding shares is at $3.7 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) stock declined by 10.11% to $4.27. The company's market cap stands at $5.6 million. </li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) shares declined by 9.91% to $0.58. The company's market cap stands at $35.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

On Friday, Centene Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) third-quarter&nbsp;sales of&nbsp;$42.02 billion, up&nbsp;10.5%&nbsp;year-over-year, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of&nbsp;$37.69 billion</a>.
Centene earned an adjusted EPS of $1.62 during the quarter, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41539767/centene-corporation-reports-third-quarter-2024-results" rel="noreferrer noopener">beating the consensus of $1.38</a>.
For the third quarter of 2024, premium and service revenues increased 6% to $36.9 billion, primarily driven by Medicaid rate increases and membership growth in the Marketplace business due to strong product positioning and overall market growth, partially offset by lower Medicaid membership primarily due to redeterminations and recent divestitures in the Other segment.
The Health benefits ratio (HBR) reached 89.2% for the third quarter, up from 87.0% a year ago, primarily driven by higher acuity in Medicaid resulting from the redetermination process Medicare Star rating impacts.
&#8220;Our diversified portfolio has allowed us to successfully navigate a dynamic landscape in the quarter. At the same time, we delivered on fundamentals that carry positive implications for Centene&#8217;s multi-year earnings trajectory, including notable RFP wins, Medicare Stars improvements, and ongoing operational efficiencies,&#8221; said Centene CEO Sarah London.
&#8220;We remain confident in our full-year outlook for adjusted diluted EPS of greater than $6.80 and are well positioned to capture the powerful, long-term growth opportunities we see in government-sponsored healthcare.&#8221;
Centene said total managed care membership increased 2.4% to 28.64 million at the end of the third quarter, compared to 27.97 million a year ago.
Centene&#8217;s enrollment in its &#8220;commercial marketplace&#8221; business grew to 4.50 million members from 3.68 million a year ago.&nbsp;Total Medicaid memberships fell 14.2% to 13.07 million.
Guidance:&nbsp;Centene reaffirms the 2024 adjusted EPS guidance floor of over $6.80 versus a consensus of $6.82.
The company&#8217;s revenue guidance has been updated to&nbsp;$159 billion—$161 billion, compared to the <a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/39984784/health-insurer-centenes-q2-premium-revenue-cushions-fall-in-medicaid-enrollment-raises-annual-outlo" rel="noreferrer noopener">prior guidance of $155.0 billion—$157.0 billion</a> and the consensus of $155.625 billion.
The 2024 HBR is expected to be around 88.3%-88.5%, compared to the high end of the previous guidance range, approximately 87.9%.
Centene increased its 2024 Premium and service revenues guidance range to $143.5 billion—$144.5 billion, compared to its prior guidance of $141 billion—$143 billion.
Price Action: CNC stock is up 13.6% at $70.02 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41528055/cdc-and-prevention-advisory-panel-backs-expanded-use-of-pfizer-and-mercks-pneumococcal-vaccines" target="_blank" rel="noreferrer noopener">CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck&#8217;s Pneumococcal Vaccines</a></li>
</ul>

Large Cap

Centene Says It Is Positioned To Capture Long-Term Growth In Government-Sponsored Healthcare, Lifts Annual Outlook

Centene shares are trading higher after the company reported better-than-expected Q3 financial results.

Centene Expects 2024 Adjusted Diluted EPS Guidance Floor Of Greater Than $6.80 Versus Consensus Of $6.81

Membership increases of 22% in Marketplace and 49% in Medicare Prescription Drug Plans, compared to the third quarter of 2023.

Centene Reported Q3 Health Benefits Ratio Of 89.2%, Total Membership Reached 28.64M

Centene Q3 2024 Adj. EPS $1.62 Beats $1.38 Estimate, Sales $42.023B Beat $37.699B Estimate

The rapidly growing aging population is driving expansion in healthcare, with rising demand for treatments and chronic disease management. Companies like AbbVie (ABBV), Medtronic (MDT), and Centene (CNC) are well-positioned to meet these needs, making them attractive options for investors seeking to capitalize on the industry's sustained growth potential. Read on… The global aging population is rising swiftly, leading to an increase in chronic illnesses linked to old age. The trend is fueling a surge in demand for medical treatments, driving significant growth in the healthcare industry. As new treatments and cures emerge, the sector's potential for future expansion is stronger than ever.
Thus, investors may find opportunities in stable healthcare stocks, AbbVie Inc. (<a href="https://stocknews.com/stock/ABBV/">ABBV</a>), Medtronic plc (<a href="https://stocknews.com/stock/MDT/">MDT</a>), and Centene Corporation (<a href="https://stocknews.com/stock/CNC/">CNC</a>). These companies are well-positioned to leverage the rising demand for age-related healthcare services, setting them up to benefit from the growing aging demographic's unique needs.
A report by the Urban Institute projects that Americans aged 65 and older will more than double, <a href="https://www.urban.org/policy-centers/cross-center-initiatives/program-retirement-policy/projects/data-warehouse/what-future-holds/us-population-aging">reaching 80 million by 2040</a>. This demographic shift is accompanied by an increase in chronic illnesses, presenting challenges but also opportunities for healthcare providers to address these needs with specialized treatments and services.
Recent innovations in pharmaceuticals are remarkable, with the U.S. Food and Drug Administration approving more drugs for chronic conditions. These advancements are helping to extend life expectancy, thus contributing to a growing elderly population in need of sustained healthcare support, fueling industry growth further.
Moreover, the industry is undergoing <a href="https://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/healthcare-tech-trends-2024.html">a technological transformation</a>. Developments in AI, precision medicine, and wearable health tech are improving patient care, increasing efficiency, and reducing disparities in healthcare access. These advancements are pivotal in meeting the needs of an expanding older population and enhancing outcomes for all patients.
Pharmaceutical companies stand to gain considerably from these trends. Statista projects the U.S. pharmaceutical market will reach a volume of $791.3 billion by 2029, growing at <a href="https://www.statista.com/outlook/hmo/pharmaceuticals/united-states">a CAGR of 4.7%</a>. This growth highlights the sector's promising future amid increasing demand for age-related healthcare solutions.
Against this backdrop, let us dive deep into the fundamentals of three healthcare stocks, starting with #3.
Stock #3: AbbVie Inc. (<a href="https://stocknews.com/stock/ABBV/">ABBV</a>)
ABBV researches, develops, manufactures, and sells medicines and therapies. The company's extensive product range includes treatments across Immunology, Oncology, Neuroscience, Eye Care, Aesthetics, and other specialties.
On October 31, ABBV partnered with EvolveImmune Therapeutics <a href="https://news.abbvie.com/2024-10-31-AbbVie-and-EvolveImmune-Therapeutics-Announce-Collaboration-and-Option-to-License-Agreement-to-Develop-Next-Generation-Cancer-Biotherapeutics">to advance multispecific biologics</a> targeting various oncology areas. The collaboration uses EvolveImmune's T-cell engager platform, helping ABBV strengthen its oncology portfolio by developing innovative antibody-based therapies for both solid tumors and hematologic cancers.
On October 28, ABBV announced plans to acquire Aliada Therapeutics, gaining access to Aliada's unique <a href="https://news.abbvie.com/2024-10-28-AbbVie-to-Acquire-Aliada-Therapeutics,-Strengthening-Focus-in-Alzheimers-Disease-and-Neuroscience-Pipeline">blood-brain barrier-crossing technology</a>. This acquisition allows ABBV to target complex central nervous system diseases, supporting growth by expanding its pipeline in high-need therapeutic areas and bolstering innovation in central nervous system (CNS) treatments.
For the fiscal third quarter that ended on September 30, 2024, ABBV's net revenues increased 3.8% year-over-year to $14.46 billion. Its operating earnings rose 68% from the prior year's quarter to $3.83 billion. Additionally, the company's adjusted earnings after tax and adjusted EPS grew 1.5% and 1.7% from their year-ago values to $5.33 billion and $3.00, respectively.
Analysts expect ABBV's revenue and <a href="https://www.investopedia.com/terms/e/eps.asp">EPS</a> for the fiscal fourth quarter (ending December 2024) to increase 3.5% and 6.7% year-over-year to $14.81 billion and $2.98, respectively. Moreover, the company topped the consensus revenue estimates in all four trailing quarters.
ABBV's stock has increased by 23.6% over the past six months and 42.5% over the past year to close the last trading session at $201.20.
ABBV's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> mirror its strong fundamentals. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
ABBV has a B grade for Growth, Value, Sentiment, and Stability. It is ranked #2 out of 161 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical – Pharmaceuticals </a>industry.
In addition to the POWR Ratings we've stated above, we also have ABBV ratings for Momentum and Quality. Get all ABBV ratings <a href="https://stocknews.com/stock/ABBV/">here</a>.
Stock #2: Medtronic plc (<a href="https://stocknews.com/stock/MDT/">MDT</a>)
MDT, based in Galway, Ireland, develops, manufactures, and distributes medical therapies. The company supplies healthcare systems, physicians, clinicians, and patients with device-based solutions across four segments: the Cardiovascular Portfolio; Neuroscience Portfolio; Medical Surgical Portfolio; and Diabetes Operating Unit.
On October 24, MDT received approval from the United States Food and Drug Administration for the Affera&#x2122; Mapping and Ablation System with Sphere-9&#x2122; Catheter. This all-in-one system, designed for treating <a href="https://news.medtronic.com/2024-10-24-A-new-paradigm-in-electrophysiology-Medtronic-receives-FDA-approval-of-Affera-TM-Mapping-and-Ablation-System-and-Sphere-9-TM-Catheter">persistent atrial fibrillation and atrial flutter</a>, positions MDT as the only company offering two pulsed field ablation technologies for atrial fibrillation.
On September 25, MDT launched several <a href="https://news.medtronic.com/2024-09-25-Medtronic-expands-AiBLE-TM-spine-surgery-ecosystem-with-new-technologies-and-Siemens-Healthineers-partnership">new software, hardware, and imaging innovations</a> to enhance AiBLE&#x2122;, its smart ecosystem. These advancements combine navigation, robotics, data, artificial intelligence, and imaging to improve outcomes in spine and cranial procedures, positioning MDT as a leader in surgical technology innovation.
For the fiscal 2025 first quarter that ended July 26, 2024, MDT's net sales increased 2.8% year-over-year to $7.92 billion. Its non-GAAP operating profit grew 2.3% from the prior year's quarter to $1.95 billion. Moreover, the company's net income attributable to MDT and EPS rose 31.7% and 35.6% from the year-ago values to $1.04 billion and $0.80, respectively.
Street expects MDT's revenue and EPS for the fiscal year ending April 2025 to increase 3.8% and 4.9% year-over-year to $33.60 billion and $5.45, respectively. Moreover, the company topped the consensus revenue and EPS estimates in all four trailing quarters, which is impressive.
MDT's shares have gained 10.2% over the past six months and 22.7% over the past year, closing the last trading session at $90.11.
MDT's solid prospects are projected in its POWR Ratings. The stock has an overall rating of B, which equates to a Buy in our proprietary rating system.
MDT has a B grade for Stability and Sentiment. It is ranked #21 out of 138 stocks in the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical – Devices &amp; Equipment</a> industry.
<a href="https://stocknews.com/stock/MDT/">Click here</a> to access MDT's ratings for Quality, Momentum, Value, and Growth.
Stock #1: Centene Corporation (<a href="https://stocknews.com/stock/CNC/">CNC</a>)
CNC provides essential healthcare programs and services to underinsured and uninsured families, commercial organizations, and military families across the United States. The company operates through Medicaid; Medicare; Commercial; and Other segments.
On May 2, CNC's Medicare business, Wellcare, partnered with Wellvana to expand <a href="https://investors.centene.com/2024-05-02-Wellcare-and-Wellvana-Announce-Partnership-to-Expand-Patient-Centered-Primary-Care-for-Benefit-of-Medicare-Advantage-Members-in-Georgia,-Tennessee-and-Texas">affordable, patient-centered primary healthcare</a> for Medicare Advantage members in Georgia, Tennessee, and Texas. The collaboration supports independent primary care physicians, improves clinical outcomes, and strengthens CNC's presence in value-based care, driving growth in its Medicare sector.
For the fiscal third quarter that ended September 30, 2024, CNC's total revenues increased 10.5% year-over-year to $42.02 billion. The net earnings and earnings per common share attributable to CNC grew 52% and 56.3% from the prior year's quarter to $713 million and $1.36, respectively.
The consensus revenue estimate of $161.28 billion for the fiscal year ending December 2024 reflects a year-over-year rise of 4.7%. Its EPS for the same period is expected to increase 2.3% from the prior year to $6.83. Also, the company topped the consensus revenue and EPS estimates in all four trailing quarters, which is impressive.
Shares of CNC marginally declined over the past five days to close the last trading session at $62.56.
CNC's POWR Ratings reflect its sound outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
CNC has a B grade for Value and Growth. Out of 10 stocks in the B-rated <a href="https://stocknews.com/category/health-insurance/">Medical – Health Insurance</a> industry, CNC is ranked #2.
To check CNC's Quality, Momentum, Sentiment, and Stability ratings, <a href="https://stocknews.com/stock/CNC/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
ABBV shares were unchanged in premarket trading Thursday. Year-to-date, ABBV has gained 34.58%, versus a 25.52% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Aanchal Sugandh</h2> <img src='https:/wp-content/uploads/2022/12/Aanchal-Sugandh_Headshot.jpg' style="float:left; padding:5px;width:125px;">Aanchal's passion for financial markets drives her work as an investment analyst and journalist. She earned her bachelor's degree in finance and is pursuing the CFA program.

She is proficient at assessing the long-term prospects of stocks with her fundamental analysis skills. Her goal is to help investors build portfolios with sustainable returns.<a href="https://stocknews.com/authors/?author=aanchal-sugandh">More...</a>The post <a href=https://stocknews.com/news/abbv-mdt-cnc-3-healthcare-stocks-to-buy-for-the-aging-population-boom/>3 Healthcare Stocks to Buy for the Aging Population Boom</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare Stocks to Buy for the Aging Population Boom

In a report released today, Steve Baxter from Wells Fargo maintained a Buy rating on Centene (CNC – Research Report), with a price target of $73.00...

Wells Fargo Sticks to Its Buy Rating for Centene (CNC)

Wells Fargo analyst Stephen Baxter lowered the firm's price target on Centene (CNC) to $73 from $90 and keeps an Overweight rating on the shares as...

Centene price target lowered to $73 from $90 at Wells Fargo

Clover Health: Buy The Dip, Reap The Rewards

President-elect Donald Trump has chosen Dr. Mehmet Oz to be administrator of Centers for Medicare and Medicaid Services. In a statement on Truth So...

Trump names Dr. Oz as administrator of Medicare and Medicaid Services

Health insurers spike as Trump picks Dr. Oz to head Medicare

Robert F Kennedy Jr, who was selected by Donald Trump to run the U.S. health and human services department, is working on plans to rid the American...

Kennedy Jr. considers upheaval to U.S. Medicare billing system, FT says

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President-...

Trump Trade: Transition team weighing White House crypto role

U.S. Managed Care Q3 2024 Earnings Recap: Medicaid/Medicare Costs Mount

UnitedHealth wins Star Ratings lawsuit against Medicare

ABBV

AXON

BITF

BTBT

COIN

CORZ

CRKN

GREE

MARA

MSTR

ONON

RIOT

SDIG

WULF

Press Releases

Health Net Only Health Plan in United States to Receive "Health Equity Accreditation Plus" Across All Lines of Business for 2024

CENTENE CORPORATION REPORTS THIRD QUARTER 2024 RESULTS

Superior HealthPlan Awards $26,000 in Grants to 13 Nonprofits and Providers

WHAT THEY ARE SAYING: 'Significant Positive Impact to…Patients,' Independent Physicians Say About $2 Million in Grants from Health Net

CENTENE NAMED ONE OF FORTUNE'S® 100 BEST LARGE WORKPLACES FOR WOMEN™ 2024

AMBETTER OF ILLINOIS EXPANDS PROVIDER NETWORK TO INCLUDE ADVOCATE HEALTH CARE

AcariaHealth Shines at the 2024 NASP Annual Meeting: Transforming Specialty Pharmacy

Contracts

CENTENE SUBSIDIARY BUCKEYE HEALTH PLAN AWARDED CONTRACT TO SERVE DUAL ELIGIBILE MEDICARE AND MEDICAID MEMBERS IN OHIO

Sunshine Health Announces the Appointment of Charlene Zein as President and CEO

Meridian Health Plan of Illinois and Liberty Bank and Trust Partner to Create Small Business Loan Program to Support and Empower Diverse and Small Businesses in Illinois

Comments

Centene

Intérêt court

Centene (NYSE:CNC) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL